| Similar Articles |
|---|
 |
The Motley Fool
July 25, 2007
Ryan Fuhrmann |
The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count.   |
The Motley Fool
April 20, 2007
Ryan Fuhrmann |
Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow. |
The Motley Fool
July 24, 2006
Ryan Fuhrmann |
The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors? |
The Motley Fool
October 5, 2006
Rich Smith |
Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors. |
The Motley Fool
July 26, 2007
Ryan Fuhrmann |
LabCorp Leaps Forward LabCorp continues to fire on all cylinders. Investors, take note. |
The Motley Fool
June 11, 2007
Billy Fisher |
Big Dollars in Diagnostic Deals CIGNA extends multi-year deals to a pair of powerhouses. The Quest agreement is a comfort to investors, who now know that Quest will continue to be a contracted provider for one of the nation's largest health insurers. |
The Motley Fool
February 15, 2007
Ryan Fuhrmann |
LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services. |
The Motley Fool
February 4, 2011
Brian Orelli |
Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you? |
The Motley Fool
February 8, 2007
Rich Duprey |
Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see. |
The Motley Fool
May 8, 2006
Tom Taulli |
Quest Software: Hugging Microsoft By expanding its products to the Microsoft line, the software company should see more growth. Investors, take note. |
The Motley Fool
January 27, 2009
Brian Orelli |
Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times. |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note. |
The Motley Fool
March 12, 2007
Ryan Fuhrmann |
Esoteric Results at Bio-Reference Labs Bio-Reference Labs is a small firm in the lab-testing field, but worth a look from investors. |
The Motley Fool
April 27, 2005
Tim Hanson |
Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio. |
The Motley Fool
April 19, 2007
Ryan Fuhrmann |
Quest Diagnostics Becomes Un-United: Fool by Numbers The lab-testing firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 25, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Standpoint Capital believes that ExxonMobil, Quest Diagnostics, and Lockheed Martin have nowhere to go but up. |
The Motley Fool
October 24, 2006
Ryan Fuhrmann |
LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings. |
The Motley Fool
September 6, 2007
Ryan Fuhrmann |
Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area. |
The Motley Fool
June 6, 2007
Ryan Fuhrmann |
Foolish Forecast: Bio-Reference Labs Nudges Competitors The clinical laboratory testing company is set to release it second-quarter earnings report. Investors, here is what you can expect to see. |
The Motley Fool
November 12, 2007
Charly Travers |
The Value of Myriad's Genes Myriad Genetics is unique in the biotech industry because it has a profitable diagnostics business to support its drug research and development efforts, as well as attractive prospects in its pipeline. Investors, take note. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
The Motley Fool
July 21, 2005
W.D. Crotty |
The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet. |
The Motley Fool
December 9, 2011
Paul Chi |
3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof. |
The Motley Fool
July 8, 2008
Dan Dzombak |
3 Stocks Hitting High Notes These stocks have just hit 52-week highs: EZCORP... Exactech... Radyne... |
The Motley Fool
October 15, 2010
Roger Friedman |
4 Stocks on David Gardner's Watchlist An array of stocks worth keeping an eye on: Financial Engines... Value Line... MercadoLibre... Quest Diagnostics... |
The Motley Fool
June 2, 2005
Tom Taulli |
Quest Fixes Broken Windows The software company's latest acquisition will help it focus on Microsoft product integration. While a tech acquisition typically rattles investors, it didn't happen with the Vintela acquisition. |
The Motley Fool
April 12, 2007
Rich Duprey |
Foolish Forecast: Checking UnitedHealth's Vitals The health services provider will report its first-quarter 2007 financial results shortly. Investors, here is what you can expect to see. |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
BusinessWeek
May 10, 2004 |
"You Just Build Up Your Confidence" Quest Diagnostics CEO-in-waiting Surya Mohapatra discusses how the five-year grooming process has helped him enter the big leagues |
InternetNews
January 29, 2004
Clint Boulton |
Active Directory Player To Join Quest Quest Software moves in on smaller rival Aelita in an attempt to shore up its Microsoft infrastructure management provisions. |
The Motley Fool
November 2, 2011
Selena Maranjian |
Make Money in Health-Care Providers the Easy Way If you expect health-care companies to thrive as our population ages, the iShares DJ US Health Care Providers ETF could save you a lot of trouble. |
The Motley Fool
April 8, 2008
Colleen Paulson |
Invest Where the Jobs Are Think about these growing sectors for your next investing opportunities. |
The Motley Fool
February 17, 2005
Rich Smith |
LabCorp Tests Positive The results show strong bottom-line growth for the health-care test provider. Compared to the pricier Quest, it's at least a relative bargain price at which investors can own an interest in this essential piece of the health-care market. |
The Motley Fool
January 22, 2007
Jack Uldrich |
GE's Plastic Surgery The shift away from the plastics business toward diagnostics is risky. Bottom line: The conglomerate could be paying a lot for something that isn't really needed, and it would be better off just trying to take better care of its existing business. |
The Motley Fool
May 2, 2006
Stephen D. Simpson |
Still Fishing for Value at Fisher At the right price, this would be an interesting play on health care and biomedical research. Investors, take note. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership. |
The Motley Fool
January 31, 2011
Dan Dzombak |
5 Small-Cap Stocks on Fire These five watchlist stocks have been on fire lately: Capstone Turbine... Avanir Pharmaceuticals... Power-One... Oilsands Quest... FuelCell Energy... |
InternetNews
June 1, 2005
Clint Boulton |
Quest Makes ID Management Move Quest Software became the latest management software vendor to bid for products that dole out identity policies, with its push to buy Vintela for $56.5 million in cash. |
The Motley Fool
November 8, 2007
Brian Orelli |
The 2 Sides of Bio-Rad Results for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales. |
Bio-IT World
February 2006
Kevin Davies |
Celera Drops Drugs for Diagnostics The company that raced to sequence the human genome, ditched its flamboyant CEO and database subscription model to become a drug development company, has decided to change course yet again. |
Fast Company
September 2006 |
Slam Excerpt Learn what was said at the Kids Philosophy Slam, a national quest for the "most philosophical students in America." |
